Abemaciclib Beneficial for HR+, HER2 − Early Breast Cancer

TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news